Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
42,400
+500 (1.19%)
At close: Sep 18, 2025
1.19%
Market Cap609.72B
Revenue (ttm)n/a
Net Income (ttm)-39.44B
Shares Out14.38M
EPS (ttm)-2,780.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,323
Average Volume64,098
Open42,600
Previous Close41,900
Day's Range41,350 - 43,400
52-Week Range19,390 - 43,400
Betan/a
RSI71.52
Earnings DateNov 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 136
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.